BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hoppu K, Anabwani G, Garcia-Bournissen F, Gazarian M, Kearns GL, Nakamura H, Peterson RG, Sri Ranganathan S, de Wildt SN. The status of paediatric medicines initiatives around the world--What has happened and what has not. Eur J Clin Pharmacol. 2012;68:1-10. [PMID: 21732178 DOI: 10.1007/s00228-011-1089-1] [Cited by in Crossref: 62] [Cited by in F6Publishing: 40] [Article Influence: 6.2] [Reference Citation Analysis]
Number Citing Articles
1 Joseph PD, Craig JC, Caldwell PH. Clinical trials in children. Br J Clin Pharmacol. 2015;79:357-369. [PMID: 24325152 DOI: 10.1111/bcp.12305] [Cited by in Crossref: 125] [Cited by in F6Publishing: 80] [Article Influence: 20.8] [Reference Citation Analysis]
2 Choonara I, Sammons H. Paediatric clinical pharmacology in the UK. Arch Dis Child 2014;99:1143-6. [PMID: 25202131 DOI: 10.1136/archdischild-2014-306853] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
3 Saiyed MM, Lalwani T, Rana D. Off-label medicine use in pediatric inpatients: a prospective observational study at a tertiary care hospital in India. Int J Pediatr 2014;2014:415815. [PMID: 25525440 DOI: 10.1155/2014/415815] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
4 Turner MA, Catapano M, Hirschfeld S, Giaquinto C; Global Research in Paediatrics. Paediatric drug development: the impact of evolving regulations. Adv Drug Deliv Rev 2014;73:2-13. [PMID: 24556465 DOI: 10.1016/j.addr.2014.02.003] [Cited by in Crossref: 89] [Cited by in F6Publishing: 61] [Article Influence: 12.7] [Reference Citation Analysis]
5 Wiernikowski JT, Macleod S; for The Working Group on Essential Medicines of the Pediatric Oncology in Developing Countries committee of SIOP. Regulatory and logistical issues influencing access to antineoplastic and supportive care medications for children with cancer in developing countries: Access to Drugs for Children in LMICs. Pediatr Blood Cancer 2014;61:1513-7. [DOI: 10.1002/pbc.25049] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Sequi M, Campi R, Clavenna A, Bonati M. Methods in pharmacoepidemiology: a review of statistical analyses and data reporting in pediatric drug utilization studies. Eur J Clin Pharmacol 2013;69:599-604. [PMID: 22832725 DOI: 10.1007/s00228-012-1354-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
7 Shimazawa R, Ikeda M. Approval status and evidence for WHO essential medicines for children in the United States, United Kingdom, and Japan: a cross-sectional study. J Pharm Policy Pract 2017;10:4. [PMID: 28070339 DOI: 10.1186/s40545-016-0094-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Nasr VG, Davis JM. Anesthetic use in newborn infants: the urgent need for rigorous evaluation. Pediatr Res 2015;78:2-6. [PMID: 25790274 DOI: 10.1038/pr.2015.58] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
9 Bruce A, Bauman M, Massicotte M. Establishing safe and effective antithrombotic therapy use in children…..finally. Thrombosis Research 2012;130:693-4. [DOI: 10.1016/j.thromres.2012.08.293] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
10 Matlock MK, Tambe A, Elliott-Higgins J, Hines RN, Miller GP, Swamidass SJ. A Time-Embedding Network Models the Ontogeny of 23 Hepatic Drug Metabolizing Enzymes. Chem Res Toxicol 2019;32:1707-21. [PMID: 31304741 DOI: 10.1021/acs.chemrestox.9b00223] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Hoppu K, Fonseca H. Why are certain age bands used for children in paediatric studies of medicines? Arch Dis Child 2021;106:631-5. [PMID: 33419728 DOI: 10.1136/archdischild-2020-319019] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Rose K, Grant-Kels JM. Pediatric melanoma-The whole (conflicts of interest) story. Int J Womens Dermatol 2019;5:110-5. [PMID: 30997384 DOI: 10.1016/j.ijwd.2018.10.020] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 4.3] [Reference Citation Analysis]
13 O'Hara K, Wright IM, Schneider JJ, Jones AL, Martin JH. Pharmacokinetics in neonatal prescribing: evidence base, paradigms and the future. Br J Clin Pharmacol 2015;80:1281-8. [PMID: 26256466 DOI: 10.1111/bcp.12741] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
14 Chin WW, Joos A. Moving toward a paradigm shift in the regulatory requirements for pediatric medicines. Eur J Pediatr 2016;175:1881-91. [PMID: 27646479 DOI: 10.1007/s00431-016-2781-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
15 De Bruyne P, Christiaens T, Boussery K, Mehuys E, Van Winckel M. Are antihistamines effective in children? A review of the evidence. Arch Dis Child 2017;102:56-60. [PMID: 27335428 DOI: 10.1136/archdischild-2015-310416] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
16 Allegaert K, Langhendries JP, van den Anker JN. Educational paper: Do we need neonatal clinical pharmacologists. Eur J Pediatr. 2012;Epub ahead of print. [PMID: 22588521 DOI: 10.1007/s00431-012-1734-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
17 Roth WJ, Kissinger CB, McCain RR, Cooper BR, Marchant-Forde JN, Vreeman RC, Hannou S, Knipp GT. Assessment of juvenile pigs to serve as human pediatric surrogates for preclinical formulation pharmacokinetic testing. AAPS J 2013;15:763-74. [PMID: 23595360 DOI: 10.1208/s12248-013-9482-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
18 Lopez-Vargas P, Tong A, Crowe S, Alexander SI, Caldwell PHY, Campbell DE, Couper J, Davidson A, De S, Fitzgerald DA, Haddad S, Hill S, Howell M, Jaffe A, James LJ, Ju A, Manera KE, McKenzie A, Morrow AM, Odgers HL, Pinkerton R, Ralph AF, Richmond P, Shaw PJ, Singh-Grewal D, van Zwieten A, Wake M, Craig JC; Kaleidoscope Project workshop investigators. Research priorities for childhood chronic conditions: a workshop report. Arch Dis Child 2019;104:237-45. [PMID: 30279157 DOI: 10.1136/archdischild-2018-315628] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
19 Rashed AN, Jackson C, Gastine S, Hsia Y, Bielicki J, Standing JF, Tomlin S, Sharland M. Pediatric pharmacokinetics of the antibiotics in the access and watch groups of the 2019 WHO model list of essential medicines for children: a systematic review. Expert Rev Clin Pharmacol 2019;12:1099-106. [PMID: 31760892 DOI: 10.1080/17512433.2019.1693257] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
20 Kim T, Han N, Sohn M, Oh JM, Lee E, Ji E, Kim I. Pharmacogenomic Biomarker Information in FDA-approved Paediatric Drug Labels. Basic Clin Pharmacol Toxicol 2015;116:438-44. [DOI: 10.1111/bcpt.12341] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
21 Vieira JML, Lima EDC, Land MGP, Ventura M, Coelho HLL. [Profile of clinical trials enrolling Brazilian children]. Cad Saude Publica 2017;33:e00169515. [PMID: 28614452 DOI: 10.1590/0102-311X00169515] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Badée J, Fowler S, de Wildt SN, Collier AC, Schmidt S, Parrott N. The Ontogeny of UDP-glucuronosyltransferase Enzymes, Recommendations for Future Profiling Studies and Application Through Physiologically Based Pharmacokinetic Modelling. Clin Pharmacokinet 2019;58:189-211. [PMID: 29862468 DOI: 10.1007/s40262-018-0681-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 17.0] [Reference Citation Analysis]
23 Adams LV, Craig SR, Mmbaga EJ, Naburi H, Lahey T, Nutt CT, Kisenge R, Noel GJ, Spielberg SP. Children's medicines in Tanzania: a national survey of administration practices and preferences. PLoS One 2013;8:e58303. [PMID: 23484012 DOI: 10.1371/journal.pone.0058303] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
24 Rose K, Grant-kels JM. The Meanings of “Pediatric Drug Development”. Ther Innov Regul Sci 2019;53:767-74. [DOI: 10.1177/2168479018812060] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
25 Sampson MR, Benjamin DK, Cohen-Wolkowiez M. Evidence-based guidelines for pediatric clinical trials: focus on StaR Child Health. Expert Rev Clin Pharmacol 2012;5:525-31. [PMID: 23121275 DOI: 10.1586/ecp.12.52] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
26 Bjerknes K, Bøyum S, Kristensen S, Brustugun J, Wang S. Manipulating tablets and capsules given to hospitalised children in Norway is common practice. Acta Paediatr 2017;106:503-8. [PMID: 27935163 DOI: 10.1111/apa.13700] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
27 Le Doare K, Barker CI, Irwin A, Sharland M. Improving antibiotic prescribing for children in the resource-poor setting. Br J Clin Pharmacol 2015;79:446-55. [PMID: 24433393 DOI: 10.1111/bcp.12320] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
28 Ruperto N, Vesely R, Saint-raymond A, Martini A; for the Paediatric Rheumatology International Trials Organisation (PRINTO). Impact of the European paediatric legislation in paediatric rheumatology: past, present and future. Ann Rheum Dis 2013;72:1893-6. [DOI: 10.1136/annrheumdis-2013-204168] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 2.9] [Reference Citation Analysis]
29 Smits A, De Cock P, Vermeulen A, Allegaert K. Physiologically based pharmacokinetic (PBPK) modeling and simulation in neonatal drug development: how clinicians can contribute. Expert Opin Drug Metab Toxicol 2019;15:25-34. [PMID: 30554542 DOI: 10.1080/17425255.2019.1558205] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
30 Balan S, Hassali MAA, Mak VSL. Two decades of off-label prescribing in children: a literature review. World J Pediatr 2018;14:528-40. [DOI: 10.1007/s12519-018-0186-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 6.7] [Reference Citation Analysis]
31 Star K, Edwards IR. Pharmacovigilance for children's sake. Drug Saf 2014;37:91-8. [PMID: 24446277 DOI: 10.1007/s40264-013-0133-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
32 Silva D, Ansotegui I, Morais-Almeida M. Off-label prescribing for allergic diseases in children. World Allergy Organ J 2014;7:4. [PMID: 24528848 DOI: 10.1186/1939-4551-7-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
33 Hoekman DR, Benninga MA. Functional constipation in childhood: current pharmacotherapy and future perspectives. Expert Opinion on Pharmacotherapy 2012;14:41-51. [DOI: 10.1517/14656566.2013.752816] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
34 Tefera YG, Gebresillassie BM, Mekuria AB, Abebe TB, Erku DA, Seid N, Beshir HB. Off-label drug use in hospitalized children: a prospective observational study at Gondar University Referral Hospital, Northwestern Ethiopia. Pharmacol Res Perspect 2017;5:e00304. [PMID: 28357130 DOI: 10.1002/prp2.304] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
35 Denburg AE, Ungar WJ, Greenberg M. Public drug policy for children in Canada. CMAJ 2017;189:E990-4. [PMID: 28760835 DOI: 10.1503/cmaj.170380] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
36 Teigen A, Wang S, Truong BT, Bjerknes K. Off-label and unlicensed medicines to hospitalised children in Norway. J Pharm Pharmacol 2017;69:432-8. [PMID: 27334565 DOI: 10.1111/jphp.12581] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
37 Allegaert K, Smits A, van den Anker JN. Drug evaluation studies in neonates: how to overcome the current limitations. Expert Rev Clin Pharmacol 2018;11:387-96. [PMID: 29421929 DOI: 10.1080/17512433.2018.1439378] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
38 Nsabagasani X, Ogwal-Okeng J, Mbonye A, Ssengooba F, Nantanda R, Muyinda H, Holme Hansen E. The "child size medicines" concept: policy provisions in Uganda. J Pharm Policy Pract 2015;8:2. [PMID: 25815197 DOI: 10.1186/s40545-015-0025-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
39 Sage DP, Kulczar C, Roth W, Liu W, Knipp GT. Persistent pharmacokinetic challenges to pediatric drug development. Front Genet 2014;5:281. [PMID: 25221567 DOI: 10.3389/fgene.2014.00281] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
40 Allegaert K. Clinical pharmacological studies in children: From exploratory towards confirmation driven methodology. World J Clin Pediatr. 2012;1:3-7. [PMID: 25254160 DOI: 10.5409/wjcp.v1.i2.3] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]